Considerable interest, speculation and controversy have been generated utilising surface-enhanced laser desorption/ionization in conjunction with mass spectrometry (SELDI-MS) 
Introduction

Despite the recent advances in molecular medicine, genomics, proteomics and translational research, our efforts to alleviate cancer have been ill reputed. According to the World Health Organisation, it is estimated that there will be 16 million new cases every year by 2020. Cancer accounts for seven million deaths every year or 12.5% of deaths worldwide. Current strategies to combat cancer include early diagnosis and administration of effective treatment and monitoring patients after treatment response. Cancer biomarkers that are currently used for the diagnosis, prognosis, monitoring of patients and prediction of therapeutic response include CA125 (ovarian), CA15.3 (breast), CA19.9 (gastrointestinal) and ␤ human chorionic gonadotropin and serum ␣-fetoprotein (testicular cancer). Due to the lack of early detection methods and specific and sensitive biomarkers, both scientist and clinicians are moving towards using proteomics as a means to (i ) discover and validate new biomarkers or ensembles of biomarkers that have better specificity and sensitivity characteristics than existing biomarker assays or cytology [1] and to (ii ) improve our understanding of cancer initiation and progression. Herein, we will discuss the applications and limitations of surfaceenhanced laser desorption/ionization-mass spectrometry (SELDI-MS) as a diagnostic and cancer biomarker discovery tool in both a clinical and scientific setting.
Surface-enhanced laser desorption/ionization-mass spectrometry
SELDI-MS, also known as ProteinChip ® , is a high-throughput proteomics technique that facilitates multiple biomarker discovery, purification and identification. The process involves binding of a crude sample to a ProteinChip array which is subsequently washed several times to insure complete removal of unbound proteins and other interfering substances such as contaminants or buffers (Fig. 1; Table 1). As in matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry, an energy absorbing matrix (EAM), such as sinapinic acid (SPA) or ␣-cyano-4-hydroxycinnamic acid matrix (CHCA), is applied to the protein spots to facilitate ionization and desorption of proteins from the surface. The mass-to-charge ratios for desorbed molecules are analysed as they fly down the TOF tube and an individual protein spectrum is generated for each sample tested.
Differentially expressed proteins are determined from the protein profiles by comparing the peak intensities of spectra. [4] .
Sampling
A wide variety of sample types can be used to detect biomarkers from crude samples, such as blood serum or plasma, intestinal fluid, cellular extracts (from microdissected cells, cell culture or xenografts), cellular secretion products, fine needle aspirates, tissue, urine and cerebrospinal fluids (CSFs). According to the literature (
Several laboratories have demonstrated the feasibility of using SELDI mass spectrometry for the diagnosis and detection of various cancers (Tables 2 and 3 [5] [6] [7] . The potential for an increase in successful treatment based on early diagnosis has driven the search for diagnostic biomarkers [5, 8] [12, 13] . Lin et al. (2006) [28] .
Smith et al. (2007) used SELDI-MS analysis to predict histological response of locally advanced rectal cancer to neoadjuvant radiochemotherapy. From 230 spectra generated representing all available time points from nine good responders (tumour regression grade [TRG] 1+2) and 11 poor responders (TRG 3-5), a cohort of 14 protein peaks were detected that collectively differentiated between good and poor responders, with 87
.5% sensitivity and 80% specificity [29] . In a Phase I clinical trial, Baker et [31] . In short, these studies highlight the potential of using SELDI-MS to predict responses to therapy. [32] . [33] . [41] . [42] . In another study, Le et [44] . [45] .
Metastasis and disease progression
A number of studies have focused on the ability of SELDI-MS to determine if protein signatures in primary cancers can predict metastasis. Nakagawa et al. (2006) showed that protein profiling can detect differential protein peaks in primary breast cancers that predict the presence and number of axillary lymph node (ALN) metastases and non-sentinel lymph node (SLN) status
In another study, Wu et al. (2002) identified and validated metastasis-associated proteins in head and neck squamous cell carcinomas (HNSCC) using SELDI-MS in conjunction with 2D-gel electrophoresis. Three proteins namely annexin I, annexin II and enolase ␣ were identified [34]. Wadsworth et al. (2004) used SELDI-MS analysis to detect sera changes between HNSCC patients versus control patients [35]. Using protein peak clustering and classification analyses of SELDI-MS
Using SELDI analysis in conjunction with MALDI-TOF/TOF MS, Dowling et al. (2007) detected and identified a 7.6 kD protein (fragment of bovine transferring) in serum-free conditioned media from paclitaxel-resistant superinvasive variant (MDA-MB-435S-F/Taxol10p4pSI) and human cancer drug-sensitive and invasive cell line (MDA-MB-435S-F)
Melle et al. (2006) used SELDI-MS to identify molecular changes occurring in hepatocellular carcinomas (HCC). Microdissected cells from control liver tissue and hepatic tumour tissues were used in this study. Using peptide fingerprint mapping and SELDI-MS, 53 proteins were identified in the tumour tissue. Ferritin light subunit (FLS) and adenylate kinase 3 ␣-like 1 (AK3) showed decreased expressions in hepatic tumour, whilst biliverdin reductase B (BVRB) was up-regulated in HCC
SELDI-MS technology has also allowed the discovery of 40 differentially expressed protein peaks between wild-type mice and mice treated with peroxisome proliferators to induce cancer in liver cells [46] . Taken together, these findings suggest that SELDI-MS in combination with mass spectrometry can be used to identify protein signatures for the detection, prognosis and the treatment of cancer from cell culture models.
Protein interactions
To further understand the biological function of a protein within a broader cellular context, the identification of protein-protein interactions is an important component [47] . Recent Lehmann et al. (2007) studied the interaction of S100 proteins, known to be involved in several human diseases such as rheumatoid arthritis and cancer [47] . Using specific immunoaffinity beads and SELDI analysis, Lehmann (2007) was able to detect specific interactions between different S100 proteins [47] . In a similar study, Hegedus et al, 2007 [58] . However, if an identified biomarker has been validated, then the SELDI-MS approach could then be used for a high-throughput, rapid-screening programme [58] .
Limitations of SELDI-MS
Another concern is the reproducibility of results between host institutions [59] [60] [61] [62] [63] 
